Immunic to highlight lead asset’s promise at upcoming Multiple Sclerosis R&D Day
Immunic Inc (NASDAQ:IMUX) announced that it will be hosting a Multiple Sclerosis (MS) Research and Development (R&D) Day on September…
0,750€
-5,18%
Echtzeit-Aktienkurs Immunic Inc.
Bid:
Ask:
Nachrichten zur Immunic Inc. Aktie
Immunic, Inc. (IMUX) Q2 2024 Earnings Call Transcript
…
Immunic strengthens leadership team as MS trials advance toward key milestones
Immunic Inc (NASDAQ:IMUX) has highlighted clinical and operational progress achieved during the second quarter, which ended June 30, 2024, and…
Immunic chief scientific officer shares insights on innovative MS therapy
To mark World Brain Day on July 22, Immunic Inc (NASDAQ:IMUX)s chief scientific officer Hella Kohlhof joined Proactive to discuss…
Immunic appoints Simona Skerjanec to board of directors
Biotechnology firm Immunic Inc (NASDAQ:IMUX) announced the appointment of Simona Skerjanec to its board of directors. Skerjanec brings nearly three…
Immunic appoints ex Novartis and Biogen exec as new COO to lead vidofludimus calcium launch
Immunic Inc (NASDAQ:IMUX) told investors it has appointed a former Novartis and Biogen executive as its new chief operating officer to lead internal…
Immunic Inc. CEO Daniel Vitt Highlights Advances in MS Treatment on World MS Day
…
Immunic, Inc. (IMUX) Q1 2024 Earnings Call Transcript
…
Immunic advances ‘potentially groundbreaking’ MS therapy vidofludimus calcium during Q1
Immunic Inc (NASDAQ:IMUX) continued to advance its clinical programs for its lead drug asset, nuclear receptor related 1 (Nurr1) activator…
Immunic publishes extended data from Phase 2 MS trial in peer-reviewed journal
Immunic Inc (NASDAQ:IMUX) has published extended data from its Phase 2 EMPhASIS trial of its lead asset vidofludimus calcium in…
Immunic granted patent for specific polymorph of vidofludimus calcium in US
Immunic Inc (NASDAQ:IMUX) has received a Notice of Allowance for a composition-of-matter patent covering a specific polymorph of vidofludimus calcium,…
Immunic to present data for lead asset vidofludimus calcium from Phase 2 MS and COVID-19 trials
Immunic Inc (NASDAQ:IMUX) announced that it will present data from its Phase 2 CALLIPER and CALVID-1 clinical trials of its…